MedPath

Safety, Tolerability, and Immunogenicity Study of a 24-Valent Pneumococcal Conjugate Vaccine (VAX-24) in Adults

Phase 1
Completed
Conditions
Pneumococcal Vaccines
Interventions
Biological: 24 valent pneumococcal conjugate vaccine
Biological: 20 valent pneumococcal conjugate vaccine
Registration Number
NCT05266456
Lead Sponsor
Vaxcyte, Inc.
Brief Summary

The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels compared to Prevnar 20™ (PCV20) in adults 18 to 49 years of age in Phase 1. The Phase 2 will evaluate the safety, tolerability, and immunogenicity of a single injection of VAX-24 at 3 dose levels compared to PCV20 in adults aged 50 to 64 years of age in Phase 2.

Detailed Description

The objective of the study is to evaluate the safety and tolerability of a single injection of VAX-24 at 3 dose levels (Low: 1.1 mcg; Mid: 2.2 mcg; or Mixed: 2.2/4.4 mcg) compared to Prevnar 20™ (PCV20) in adults 18 to 49 years of age in Phase 1. The Phase 2 will evaluate the safety, tolerability, and immunogenicity of a single injection of VAX-24 at 3 dose levels (Low: 1.1 mcg; Mid: 2.2 mcg; or Mixed: 2.2/4.4 mcg) compared to PCV20 in adults aged 50 to 64 years of age.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
835
Inclusion Criteria
  • Male or female age 18 to 49 years (inclusive) for the Phase 1 group, or 50 to 64 years (inclusive) for the Phase 2 group at the time of enrollment into the study.
  • Able and willing to complete the informed consent process.
  • Available for clinical follow-up through the last study visit at 6 months after the study vaccination.
  • In good general health as determined by medical history, vital signs, physical examination, and clinical judgment of the investigator.
  • Screening laboratory values must be within the central laboratory normal limits prior to study enrollment. Minor abnormalities are considered acceptable if not clinically significant.
  • Willing to have blood samples collected, stored indefinitely, and used for research purposes.
  • Able to provide proof of identity to the satisfaction of the study staff completing the enrollment process.
  • Negative pregnancy test (urine and serum) for women of childbearing potential.
Read More
Exclusion Criteria
  • Previous pneumococcal disease (either confirmed or by self-reporting).
  • Previous receipt of a licensed or investigational pneumococcal vaccine.
  • Receipt of any investigational study product within 30 days prior to enrollment into the study, currently participating in another interventional investigational study, or having plans to receive another investigational product(s) while on study.
  • Planned or actual administration of any licensed vaccine during the period starting 30 days before enrollment into the study through Day 29.
  • Physical examination indicating any clinically significant medical condition.
  • Body Temperature > 38.0°C (> 100.4°F) or acute illness within 3 days prior to study vaccination (subject may be rescheduled).
  • Seropositive to HIV, HCV, or HBsAg.
  • History of severe allergic reaction with generalized urticaria, angioedema, or anaphylaxis.
  • Female who is breast-feeding or planning to become pregnant during study participation.
  • Bleeding disorder diagnosed by a doctor (eg, factor deficiency, coagulopathy, or platelet disorder requiring special precautions) or significant bruising or bleeding difficulties with IM injections or blood draws.
  • Any other chronic or clinically significant medical condition that, in the opinion of the investigator, would jeopardize the safety or rights of the subject or confound evaluation of the study vaccine.
  • Any medical, psychiatric, or social condition that, in the judgment of the investigator, is a contraindication to protocol participation or impairs a subject's ability to give informed consent.
  • Received blood or blood product (including Immune Globulin IV) within 90 days prior to enrollment into the study.
  • Received systemic corticosteroids for ≥ 14 consecutive days and has not completed treatment ≤30 days prior to enrollment into the study.
  • Receiving immunosuppressive therapy.
  • History of malignancy ≤5 years before enrollment, except for adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer.
Read More

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
VAX-24 Mid Dose24 valent pneumococcal conjugate vaccineParticipants will receive a single dose of VAX-24 2.2 mcg administered as an intramuscular injection on Day 1.
VAX-24 Mixed Dose24 valent pneumococcal conjugate vaccineParticipants will receive a single dose of VAX-24 2.2 mcg/4.4 mcg administered as an intramuscular injection on Day 1.
PCV2020 valent pneumococcal conjugate vaccineParticipants will receive a single intramuscular injection of the standard dose of PCV20 on Day 1.
VAX-24 Low Dose24 valent pneumococcal conjugate vaccineParticipants will receive a single dose of VAX-24 1.1 mcg administered as an intramuscular injection on Day 1.
Primary Outcome Measures
NameTimeMethod
Percentage of Participants Reporting SAEs and New Onset of Chronic Illnesses (NOCI)6 months after vaccination

Percentage of participants with SAEs and NOCIs

Percentage of Participants Reporting Solicited Systemic Events Within 7 Days After Vaccination in Each Age Group7 days after vaccination

Solicited systemic reactions include fever, headache, fatigue, muscle pain, and joint pain

Percentage of Participants Reporting Solicited Local Reactions Within 7 Days After Vaccination in Each Age Group7 days after vaccination

Solicited local reactions include redness/erythema, swelling/induration, and pain at injection site within 7 days after vaccination in each age group

Percentage of Participants Reporting Unsolicited Adverse Events (AE) in Each Age Group1 month after vaccination

Percentage of participants in each age group with adverse events (AEs) whose date of onset occurs after the study vaccine and within the 28 days after vaccination.

Secondary Outcome Measures
NameTimeMethod
VAX-24 Pneumococcal Serotype-specific Immunoglobulin G (IgG) Geometric Mean Concentration (GMCs)1 month after vaccination

Antibody geometric mean concentrations as measured by IgG for the 24 pneumococcal serotypes in VAX-24

Percentage of Participants With Laboratory Value Abnormalities and/or Potentially Clinically Significant Laboratory Values1 month after vaccination

Shifts from Normal at Baseline to Abnormal on Day 29 in Clinical Chemistry Parameters Occurring in \>5% of Subjects Aged 50 to 64 Years

VAX-24 Pneumococcal Serotype-specific Opsonophagocytic Assay (OPA) Geometric Mean Titer (GMTs)1 month after vaccination

Antibody geometric mean titers as measured by OPA for the 24 pneumococcal serotypes in VAX-24

Trial Locations

Locations (11)

Meridian Clinical Research

🇺🇸

Savannah, Georgia, United States

Benchmark Research

🇺🇸

San Angelo, Texas, United States

Johnson County Clin-Trials

🇺🇸

Lenexa, Kansas, United States

CenExel RCA

🇺🇸

Hollywood, Florida, United States

Coastal Carolina Research

🇺🇸

North Charleston, South Carolina, United States

Rochester Clinical Research

🇺🇸

Rochester, New York, United States

Acellacare of Wilmington

🇺🇸

Wilmington, North Carolina, United States

Precision Clinical Research

🇺🇸

Sunrise, Florida, United States

Velocity Clinical Research

🇺🇸

Warwick, Rhode Island, United States

Alliance for Multispecialty Research

🇺🇸

Kansas City, Missouri, United States

JBR Clinical Research

🇺🇸

Salt Lake City, Utah, United States

© Copyright 2025. All Rights Reserved by MedPath